KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Assets (2016 - 2025)

NovoCure's Non-Current Assets history spans 12 years, with the latest figure at $157.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 17.43% year-over-year to $157.6 million; the TTM value through Dec 2025 reached $500.7 million, up 273.05%, while the annual FY2025 figure was $157.6 million, 17.43% up from the prior year.
  • Non-Current Assets for Q4 2025 was $157.6 million at NovoCure, down from $161.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $162.6 million in Q2 2025 and bottomed at $51.4 million in Q3 2021.
  • The 5-year median for Non-Current Assets is $95.9 million (2023), against an average of $102.0 million.
  • The largest annual shift saw Non-Current Assets increased 8.16% in 2021 before it soared 39.64% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $66.0 million in 2021, then grew by 21.45% to $80.1 million in 2022, then soared by 39.44% to $111.7 million in 2023, then rose by 20.13% to $134.2 million in 2024, then increased by 17.43% to $157.6 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Non-Current Assets are $157.6 million (Q4 2025), $161.3 million (Q3 2025), and $162.6 million (Q2 2025).